Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
2 hedge funds and large institutions have $216 invested in Zivo Bioscience, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 10 closing their positions.
83% less funds holding
Funds holding: 12 → 2 (-10)
100% less capital invested
Capital invested by funds: $1.61M → $216 (-$1.61M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 10
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.04M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$360K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$170K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$14.7K |
| 5 |
VCA
Verdence Capital Advisors
Hunt Valley,
Maryland
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCWM
1
Bartlett & Co Wealth Management
Cincinnati,
Ohio
| $216 | -$3 | -1 | -0.6% |
|
|
AC
2
Armistice Capital
New York
| – | -$1.04M | -133,645 | Closed |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| – | -$360K | -45,475 | Closed |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| – | -$170K | -21,811 | Closed |
|
|
5
Wells Fargo
San Francisco,
California
| – | -$14.7K | -1,888 | Closed |
|
|
VCA
6
Verdence Capital Advisors
Hunt Valley,
Maryland
| – | -$13K | -1,667 | Closed |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$6.96K | -892 | Closed |
|
8
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$818 | -105 | Closed |
|
|
BCM
9
Bourgeon Capital Management
Darien,
Connecticut
| – | -$41 | -5 | Closed |
|
10
JP Morgan Chase
New York
| – | -$12 | -2 | Closed |
|
|
BC
11
Bartlett & Co
Cincinnati,
Ohio
| – | -$3 | -1 | -0.6% |
|
ZIVO Hedge Fund Activity: Q4 2023 in Review
2 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q4 2023, worth a combined $216 — down 100% from $1.61M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ZIVO and 0 opened new positions — a net loss of 10 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $1.04M sold.
- 2 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q4 2023, down from 12 in Q3 2023.
- Funds reported $216 of Zivo Bioscience, Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Zivo Bioscience, Inc. Common Stock positions in Q4 2023 and 10 closed out, a net change of -10 holders.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q4 2023 was Armistice Capital, an estimated $1.04M sold.
Based on aggregated 13F filings for Q4 2023.